{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T00:05:08Z","timestamp":1759017908209,"version":"3.44.0"},"reference-count":98,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009104","name":"Universit\u00e0 Degli Studi di Modena e Reggio Emila","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009104","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.clinthera.2021.01.020","type":"journal-article","created":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T04:16:48Z","timestamp":1613535408000},"page":"654-670","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Rational Use of Lasmiditan for Acute Migraine Treatment in Adults: A Narrative Review"],"prefix":"10.1016","volume":"43","author":[{"given":"Anna","family":"Ferrari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8917-9980","authenticated-orcid":false,"given":"Cecilia","family":"Rustichelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2021.01.020_bib1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/head.13301","article-title":"Migraine burden of disease: from the patient's experience to a socio-economic view: supplement article","volume":"58","author":"Agosti","year":"2018","journal-title":"Headache"},{"key":"10.1016\/j.clinthera.2021.01.020_bib2","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.molmed.2006.11.005","article-title":"Recent advances in understanding migraine mechanisms, molecules and therapeutics","volume":"13","author":"Goadsby","year":"2007","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.clinthera.2021.01.020_bib3","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1007\/s10072-016-2705-8","article-title":"Psychosocial difficulties in patients with episodic migraine: a cross-sectional study","volume":"37","author":"Raggi","year":"2016","journal-title":"Neurol Sci"},{"key":"10.1016\/j.clinthera.2021.01.020_bib4","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1001\/archneurpsyc.1938.02270040093005","article-title":"Mechanism of migraine headache and action of ergotamine tartrate","volume":"39","author":"Graham","year":"1938","journal-title":"Arch Neur Psych"},{"key":"10.1016\/j.clinthera.2021.01.020_bib5","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1001\/archsurg.1940.01210040002001","article-title":"Experimental studies on headache: pain-sensitive structures of the head and their significance in headache","volume":"41","author":"Ray","year":"1940","journal-title":"Arch Surg"},{"key":"10.1016\/j.clinthera.2021.01.020_bib6","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3389\/fncel.2018.00233","article-title":"Vascular contributions to migraine: time to revisit?","volume":"12","author":"Mason","year":"2018","journal-title":"Front Cel Neurosci"},{"key":"10.1016\/j.clinthera.2021.01.020_bib7","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1517\/13543784.10.10.1831","article-title":"Advances in pharmacological treatment of migraine","volume":"10","author":"Diener","year":"2001","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.clinthera.2021.01.020_bib8","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/brain\/awn321","article-title":"The vascular theory of migraine - a great story wrecked by the facts","volume":"132","author":"Goadsby","year":"2009","journal-title":"Brain"},{"key":"10.1016\/j.clinthera.2021.01.020_bib9","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1177\/0333102419867280","article-title":"Hypothalamic regulation of headache and migraine","volume":"39","author":"May","year":"2019","journal-title":"Cephalalgia"},{"key":"10.1016\/j.clinthera.2021.01.020_bib10","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.brainresrev.2004.09.007","article-title":"Neurobiology in primary headaches","volume":"48","author":"Edvinsson","year":"2005","journal-title":"Brain Res Brain Res Rev"},{"key":"10.1016\/j.clinthera.2021.01.020_bib11","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/head.13081","article-title":"The trigeminovascular pathway: role of CGRP and CGRP receptors in migraine","volume":"57","author":"Edvinsson","year":"2017","journal-title":"Headache"},{"key":"10.1016\/j.clinthera.2021.01.020_bib12","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1056\/NEJMra010917","article-title":"Migraine - current understanding and treatment","volume":"346","author":"Goadsby","year":"2002","journal-title":"N\u00a0Eng J Med"},{"key":"10.1016\/j.clinthera.2021.01.020_bib13","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.pharmthera.2009.09.003","article-title":"The role of CGRP in the pathophysiology of migraine and efficacy of CGRP receptor antagonists as acute antimigraine drugs","volume":"124","author":"Villal\u00f3n","year":"2009","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2021.01.020_bib14","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s40263-013-0136-0","article-title":"Cranioselectivity of sumatriptan revisited: pronounced contractions to sumatriptan in small human isolated coronary artery","volume":"28","author":"Chan","year":"2014","journal-title":"CNS Drugs"},{"key":"10.1016\/j.clinthera.2021.01.020_bib15","first-page":"3","article-title":"Comparison of the vasoconstrictor properties of the 5-HT1D-receptor agonists rizatriptan (MK-462) and sumatriptan in human isolated coronary artery: outcome of two independent studies using different experimental protocols","volume":"12","author":"Longmore","year":"1997","journal-title":"Funct Neurol"},{"key":"10.1016\/j.clinthera.2021.01.020_bib16","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1212\/WNL.55.10.1524","article-title":"Craniovascular selectivity of eletriptan and sumatriptan in human isolated blood vessels","volume":"55","author":"MaassenVanDenBrink","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2021.01.020_bib17","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/j.1526-4610.2004.04078.x","article-title":"Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine","volume":"44","author":"Dodick","year":"2004","journal-title":"Headache"},{"key":"10.1016\/j.clinthera.2021.01.020_bib18","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s00210-004-0941-6","article-title":"Involvement of 5-HT1B receptors in triptan-induced contractile responses in Guinea-pig isolated iliac artery","volume":"370","author":"J\u00e4hnichen","year":"2004","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.clinthera.2021.01.020_bib19","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/j.1526-4610.1994.hed3407394.x","article-title":"Peripheral and central trigeminovascular activation in cat is blocked by the serotonin (5HT)-1D receptor agonist 311C90","volume":"34","author":"Goadsby","year":"1994","journal-title":"Headache"},{"key":"10.1016\/j.clinthera.2021.01.020_bib20","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.brainres.2014.11.031","article-title":"Localization of CGRP, CGRP receptor, PACAP and glutamate in trigeminal ganglion. Relation to the blood\u2013brain barrier","volume":"1600","author":"Eftekhari","year":"2015","journal-title":"Brain Res"},{"key":"10.1016\/j.clinthera.2021.01.020_bib21","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1111\/j.1468-2982.2006.01219.x","article-title":"Intravital microscopy on a closed cranial window in mice: a model to study trigeminovascular mechanisms involved in migraine","volume":"26","author":"Gupta","year":"2006","journal-title":"Cephalalgia"},{"key":"10.1016\/j.clinthera.2021.01.020_bib22","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.pain.2012.01.005","article-title":"mRNA expression of 5-hydroxytryptamine 1B, 1D, and 1F receptors and their role in controlling the release of calcitonin gene-related peptide in the rat trigeminovascular system","volume":"153","author":"Amrutkar","year":"2012","journal-title":"Pain"},{"key":"10.1016\/j.clinthera.2021.01.020_bib23","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/ana.410280213","article-title":"Vasoactive peptide release in the extracerebral circulation of humans during migraine headache","volume":"28","author":"Goadsby","year":"1990","journal-title":"Ann Neurol"},{"key":"10.1016\/j.clinthera.2021.01.020_bib24","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1468-2982.2005.00836.x","article-title":"Sumatriptan causes parallel decrease in plasma calcitonin gene-related peptide (CGRP) concentration and migraine headache during nitroglycerin induced migraine attack","volume":"25","author":"Juhasz","year":"2005","journal-title":"Cephalalgia"},{"key":"10.1016\/j.clinthera.2021.01.020_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0026-895X(25)08798-X","article-title":"The rat 5-hydroxytryptamine1B receptor is the species homologue of the human 5-hydroxytryptamine1D beta receptor","volume":"41","author":"Adham","year":"1992","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.clinthera.2021.01.020_bib26","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1093\/brain\/120.12.2171","article-title":"Microiontophoretic application of serotonin (5HT)1B\/1D agonists inhibits trigeminal cell firing in the cat","volume":"120","author":"Storer","year":"1997","journal-title":"Brain"},{"key":"10.1016\/j.clinthera.2021.01.020_bib27","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.pharmthera.2018.01.005","article-title":"Is selective 5-HT1F receptor agonism an entity apart from that of the triptans in antimigraine therapy?","volume":"186","author":"Rubio-Beltr\u00e1n","year":"2018","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2021.01.020_bib28","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s10194-020-01132-3","article-title":"Lasmiditan mechanism of action - review of a selective 5-HT1F agonist","volume":"21","author":"Clemow","year":"2020","journal-title":"J\u00a0Headache Pain"},{"key":"10.1016\/j.clinthera.2021.01.020_bib29","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s13311-018-0615-6","article-title":"Targeted 5-HT1F therapies for migraine","volume":"15","author":"Vila-Pueyo","year":"2018","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.clinthera.2021.01.020_bib30","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/S0140-6736(01)06347-4","article-title":"Selective serotonin 1F (5-HT(1F)) receptor agonist LY334370 for acute migraine: a randomised controlled trial","volume":"358","author":"Goldstein","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2021.01.020_bib31","doi-asserted-by":"crossref","first-page":"547","DOI":"10.2147\/NDT.S25531","article-title":"Emerging therapeutic options for acute migraine: focus on the potential of lasmiditan","volume":"10","author":"Rizzoli","year":"2014","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.clinthera.2021.01.020_bib32","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/17425255.2019.1578749","article-title":"Pharmacokinetics and pharmacodynamics of new acute treatments for migraine","volume":"15","author":"Lupi","year":"2019","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.clinthera.2021.01.020_bib33","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1177\/0333102410370873","article-title":"Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan","volume":"30","author":"Nelson","year":"2010","journal-title":"Cephalalgia"},{"key":"10.1016\/j.clinthera.2021.01.020_bib34","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s40263-019-00665-9","article-title":"Recent advances in pharmacotherapy for episodic migraine","volume":"33","author":"Chan","year":"2019","journal-title":"CNS Drugs"},{"key":"10.1016\/j.clinthera.2021.01.020_bib35","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1046\/j.1468-2982.1997.1706631.x","article-title":"Migraine therapy: relationship between serotonergic contractile receptors in canine and rabbit saphenous veins to human cerebral and coronary arteries","volume":"17","author":"Cohen","year":"1997","journal-title":"Cephalalgia"},{"key":"10.1016\/j.clinthera.2021.01.020_bib36","doi-asserted-by":"crossref","first-page":"4681","DOI":"10.1111\/bph.14832","article-title":"Characterization of binding, functional activity, and contractile responses of the selective 5-HT1F receptor agonist lasmiditan","volume":"176","author":"Rubio-Beltr\u00e1n","year":"2019","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.clinthera.2021.01.020_bib37","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.nurt.2010.03.003","article-title":"5-HT(1F) receptor agonists: a new treatment option for migraine attacks?","volume":"7","author":"Neeb","year":"2010","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.clinthera.2021.01.020_bib38","first-page":"103","article-title":"Lasmiditan acts specifically on the 5-HT1F receptor in the central nervous system","volume":"36","author":"Kovalchin","year":"2016","journal-title":"Cephalalgia"},{"key":"10.1016\/j.clinthera.2021.01.020_bib39","first-page":"362","article-title":"Lasmiditan inhibits CGRP release in the mouse trigeminovascular system","volume":"37","author":"Labastida-Ram\u00edrez","year":"2017","journal-title":"Cephalalgia"},{"key":"10.1016\/j.clinthera.2021.01.020_bib40","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0306-4522(03)00570-0","article-title":"Evidence for serotonin (5-HT)1B, 5-HT1D and 5-HT1F receptor inhibitory effects on trigeminal neurons with craniovascular input","volume":"122","author":"Goadsby","year":"2003","journal-title":"Neuroscience"},{"key":"10.1016\/j.clinthera.2021.01.020_bib41","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.neulet.2009.09.008","article-title":"Colocalization of 5-HT1F receptor and calcitonin gene-related peptide in rat vestibular nuclei","volume":"465","author":"Ahn","year":"2009","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.clinthera.2021.01.020_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11940-010-0105-6","article-title":"Acute migraine therapy: new drugs and new approaches","volume":"13","author":"Monteith","year":"2011","journal-title":"Curr Treat Options Neurol"},{"key":"10.1016\/j.clinthera.2021.01.020_bib43","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s40263-019-00630-6","article-title":"Pathophysiological mechanisms in migraine and the identification of new therapeutic targets","volume":"33","author":"Haanes","year":"2019","journal-title":"CNS Drugs"},{"key":"10.1016\/j.clinthera.2021.01.020_bib44","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1124\/jpet.119.262410","article-title":"5-hydroxytryptamine 1F receptor agonist induces mitochondrial biogenesis and promotes recovery from spinal cord injury","volume":"372","author":"Simmons","year":"2020","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.clinthera.2021.01.020_bib45","first-page":"52","article-title":"Mitochondrial migraine: disentangling the angiopathy paradigm in m.3243A>G patients","volume":"46","author":"Smeitink","year":"2019","journal-title":"JIMD Rep"},{"key":"10.1016\/j.clinthera.2021.01.020_bib46","first-page":"24","article-title":"COL-144, an orally bioavailable selective 5-HT1F receptor agonist for acute migraine therapy","volume":"29","author":"Pilgrim","year":"2009","journal-title":"Cephalalgia"},{"key":"10.1016\/j.clinthera.2021.01.020_bib47","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1080\/13543784.2017.1280457","article-title":"Lasmiditan for the treatment of migraine","volume":"26","author":"Capi","year":"2017","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.clinthera.2021.01.020_bib48","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1177\/0333102410375512","article-title":"Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan - a randomised proof-of-concept trial","volume":"30","author":"Ferrari","year":"2010","journal-title":"Cephalalgia"},{"key":"10.1016\/j.clinthera.2021.01.020_bib49","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S1474-4422(12)70047-9","article-title":"Efficacy and tolerability of lasmiditan, an oral 5-HT(1F) receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study","volume":"11","author":"F\u00e4rkkil\u00e4","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.clinthera.2021.01.020_bib50","doi-asserted-by":"crossref","first-page":"e2222","DOI":"10.1212\/WNL.0000000000006641","article-title":"Lasmiditan is an effective acute treatment for migraine: a phase 3 randomized study","volume":"91","author":"Kuca","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2021.01.020_bib51","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1093\/brain\/awz134","article-title":"Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine","volume":"142","author":"Goadsby","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.clinthera.2021.01.020_bib52","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1177\/0333102419864132","article-title":"Interim results of a prospective, randomized, open-label, phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study)","volume":"39","author":"Brandes","year":"2019","journal-title":"Cephalalgia"},{"key":"10.1016\/j.clinthera.2021.01.020_bib53","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1177\/0333102419889350","article-title":"Lasmiditan for the acute treatment of migraine: subgroup analyses by prior response to triptans","volume":"40","author":"Knievel","year":"2020","journal-title":"Cephalalgia"},{"key":"10.1016\/j.clinthera.2021.01.020_bib54","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s10194-019-0974-3","article-title":"Therapeutic novelties in migraine: new drugs, new hope?","volume":"20","author":"Do","year":"2019","journal-title":"J\u00a0Headache Pain"},{"key":"10.1016\/j.clinthera.2021.01.020_bib55","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1080\/14728214.2018.1552939","article-title":"Emerging drugs for migraine treatment: an update","volume":"23","author":"Lambru","year":"2018","journal-title":"Expert Opin Emerg Drugs"},{"key":"10.1016\/j.clinthera.2021.01.020_bib56","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1111\/head.13636","article-title":"Onset of efficacy following oral treatment with lasmiditan for the acute treatment of migraine: integrated results from 2 randomized double-blind placebo-controlled phase 3 clinical studies","volume":"59","author":"Ashina","year":"2019","journal-title":"Headache"},{"key":"10.1016\/j.clinthera.2021.01.020_bib57","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1080\/03007995.2020.1808780","article-title":"Lasmiditan in patients with common migraine comorbidities: a post hoc efficacy and safety analysis of two phase 3 randomized clinical trials","volume":"36","author":"Clemow","year":"2020","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2021.01.020_bib58","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1177\/0333102419859313","article-title":"Sustained responses to lasmiditan: results from post-hoc analyses of two phase 3 randomized clinical trials for acute treatment of migraine","volume":"39","author":"Doty","year":"2019","journal-title":"Cephalalgia"},{"key":"10.1016\/j.clinthera.2021.01.020_bib59","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1177\/0333102419855080","article-title":"Safety findings from phase 3 lasmiditan studies for acute treatment of migraine: results from SAMURAI and SPARTAN","volume":"39","author":"Krege","year":"2019","journal-title":"Cephalalgia"},{"key":"10.1016\/j.clinthera.2021.01.020_bib60","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s12883-019-1420-5","article-title":"Effect of a rescue or recurrence dose of lasmiditan on efficacy and safety in the acute treatment of migraine: findings from the phase 3 trials (SAMURAI and SPARTAN)","volume":"19","author":"Loo","year":"2019","journal-title":"BMC Neurol"},{"key":"10.1016\/j.clinthera.2021.01.020_bib61","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s10194-019-1032-x","article-title":"Efficacy and safety of lasmiditan in patients using concomitant migraine preventive medications: findings from SAMURAI and SPARTAN, two randomized phase 3 trials","volume":"20","author":"Loo","year":"2019","journal-title":"J\u00a0Headache Pain"},{"key":"10.1016\/j.clinthera.2021.01.020_bib62","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s10194-019-1044-6","article-title":"Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors: post-hoc analysis of pooled results from 2 randomized, double-blind, placebo-controlled, phase 3 trials","volume":"20","author":"Shapiro","year":"2019","journal-title":"J\u00a0Headache Pain"},{"key":"10.1016\/j.clinthera.2021.01.020_bib63","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s40120-020-00185-5","article-title":"Improvement in function after lasmiditan treatment: post hoc analysis of data from phase 3 studies","volume":"9","author":"Smith","year":"2020","journal-title":"Neurol Ther"},{"key":"10.1016\/j.clinthera.2021.01.020_bib64","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1111\/head.13544","article-title":"Characterization of dizziness after lasmiditan usage: findings from the SAMURAI and SPARTAN acute migraine treatment randomized trials","volume":"59","author":"Tepper","year":"2019","journal-title":"Headache"},{"key":"10.1016\/j.clinthera.2021.01.020_bib65","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1111\/head.13897","article-title":"Evaluation of 2-hour post-dose efficacy of lasmiditan for the acute treatment of difficult-to-treat migraine attacks","volume":"60","author":"Tepper","year":"2020","journal-title":"Headache"},{"key":"10.1016\/j.clinthera.2021.01.020_bib66","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s10194-020-01088-4","article-title":"Trajectory of migraine-related disability following long-term treatment with lasmiditan: results of the GLADIATOR study","volume":"21","author":"Lipton","year":"2020","journal-title":"J\u00a0Headache Pain"},{"key":"10.1016\/j.clinthera.2021.01.020_bib67","first-page":"1","article-title":"Long-term safety and efficacy of lasmiditan for acute treatment of migraine: final results of the GLADIATOR study","volume":"3","author":"Brandes","year":"2020","journal-title":"Cephalalgia Rep"},{"key":"10.1016\/j.clinthera.2021.01.020_bib68","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s10194-020-01138-x","article-title":"Short-term efficacy and safety of lasmiditan, a novel 5-HT1F receptor agonist, for the acute treatment of migraine: a systematic review and meta-analysis","volume":"21","author":"Hou","year":"2020","journal-title":"J\u00a0Headache Pain"},{"key":"10.1016\/j.clinthera.2021.01.020_bib69","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/head.13731","article-title":"Issues impacting adverse event frequency and severity: differences between randomized phase 2 and phase 3 clinical trials for lasmiditan","volume":"60","author":"Kudrow","year":"2020","journal-title":"Headache"},{"key":"10.1016\/j.clinthera.2021.01.020_bib70","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s40263-020-00753-1","article-title":"Lasmiditan for acute treatment of migraine in adults: a systematic review and meta-analysis of randomized controlled trials","volume":"34","author":"Yang","year":"2020","journal-title":"CNS Drugs"},{"key":"10.1016\/j.clinthera.2021.01.020_bib71","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/WNF.0000000000000417","article-title":"The efficacy of lasmiditan for the treatment of migraine: a meta-analysis of randomized controlled studies","volume":"43","author":"Zhu","year":"2020","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.clinthera.2021.01.020_bib72","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1111\/head.13899","article-title":"Pain freedom at 2 to 8 hours with lasmiditan: a comparison with rimegepant and ubrogepant","volume":"60","author":"Doty","year":"2020","journal-title":"Headache"},{"key":"10.1016\/j.clinthera.2021.01.020_bib73","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1007\/s40265-019-01225-7","article-title":"Lasmiditan: first approval","volume":"79","author":"Lamb","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2021.01.020_bib74","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1177\/1756285614562419","article-title":"The pharmacological profile and clinical prospects of the oral 5-HT1F receptor agonist lasmiditan in the acute treatment of migraine","volume":"8","author":"Reuter","year":"2015","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.clinthera.2021.01.020_bib75","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1080\/14656566.2019.1694004","article-title":"Profiling lasmiditan as a treatment option for migraine","volume":"21","author":"Curto","year":"2020","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.clinthera.2021.01.020_bib76","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1097\/j.pain.0000000000001801","article-title":"Lasmiditan inhibits calcitonin gene-related peptide release in the rodent trigeminovascular system","volume":"161","author":"Labastida-Ram\u00edrez","year":"2020","journal-title":"Pain"},{"key":"10.1016\/j.clinthera.2021.01.020_bib77","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1111\/head.13798","article-title":"Lasmiditan for the acute treatment of migraine","volume":"60","author":"Tepper","year":"2020","journal-title":"Headache"},{"key":"10.1016\/j.clinthera.2021.01.020_bib78","doi-asserted-by":"crossref","DOI":"10.1002\/hup.2732","article-title":"Effects of lasmiditan on simulated driving performance: results of two randomized, blinded, crossover studies with placebo and active controls","volume":"35","author":"Pearlman","year":"2020","journal-title":"Hum Psychopharmacol"},{"key":"10.1016\/j.clinthera.2021.01.020_bib80","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S1092852917000864","article-title":"Current management: migraine headache","volume":"22","author":"Silberstein","year":"2017","journal-title":"CNS Spectr"},{"key":"10.1016\/j.clinthera.2021.01.020_bib81","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1111\/head.12154","article-title":"Examination of unmet treatment needs among persons with episodic migraine: results of the American Migraine Prevalence and Prevention (AMPP) study","volume":"53","author":"Lipton","year":"2013","journal-title":"Headache"},{"key":"10.1016\/j.clinthera.2021.01.020_bib82","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1080\/17425255.2018.1416097","article-title":"Side effects associated with current and prospective antimigraine pharmacotherapies","volume":"14","author":"Gonz\u00e1lez-Hern\u00e1ndez","year":"2018","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.clinthera.2021.01.020_bib83","doi-asserted-by":"crossref","first-page":"107528","DOI":"10.1016\/j.pharmthera.2020.107528","article-title":"Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans","volume":"211","author":"de Vries","year":"2020","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2021.01.020_bib84","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1517\/13543784.2014.861817","article-title":"Drugs targeting 5-hydroxytryptamine receptors in acute treatments of migraine attacks. A review of new drugs and new administration forms of established drugs","volume":"23","author":"Tfelt-Hansen","year":"2014","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.clinthera.2021.01.020_bib85","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1056\/NEJMra1915327","article-title":"Migraine","volume":"383","author":"Ashina","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clinthera.2021.01.020_bib86","article-title":"Novel therapies in acute migraine management: small-molecule calcitonin gene-receptor antagonists and serotonin 1F receptor agonist","author":"Joyner","year":"2020","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.clinthera.2021.01.020_bib87","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/j.1468-2982.2004.00694.x","article-title":"Triptans and CNS side-effects: pharmacokinetic and metabolic mechanisms","volume":"24","author":"Dodick","year":"2004","journal-title":"Cephalalgia"},{"key":"10.1016\/j.clinthera.2021.01.020_bib88","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s00228-004-0864-7","article-title":"Adverse reactions related to drugs for headache treatment: clinical impact","volume":"60","author":"Ferrari","year":"2005","journal-title":"Eur J Clin Pharmacol"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2021.01.020_bib89","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1046\/j.1526-4610.2002.0420s1003.x","article-title":"What do patients with migraine want from acute migraine treatment?","volume":"42","author":"Lipton","year":"2002","journal-title":"Headache"},{"key":"10.1016\/j.clinthera.2021.01.020_bib90","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1468-2982.2004.00893.x","article-title":"What do patients want from acute migraine treatment?","volume":"24","author":"Gallagher","year":"2004","journal-title":"Cephalalgia"},{"key":"10.1016\/j.clinthera.2021.01.020_bib92","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0098933","article-title":"What do patients consider to be the most important outcomes for effectiveness studies on migraine treatment? Results of a Delphi study","volume":"9","author":"Smelt","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.clinthera.2021.01.020_bib93","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/jcph.1543","article-title":"Abuse potential of lasmiditan: a phase 1 randomized, placebo- and alprazolam-controlled crossover study","volume":"60","author":"Wilbraham","year":"2020","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2021.01.020_bib94","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1517\/17425255.2015.1043265","article-title":"Medication overuse and chronic migraine: a critical review according to clinical pharmacology","volume":"11","author":"Ferrari","year":"2015","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.clinthera.2021.01.020_bib95","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1177\/0333102420920006","article-title":"Evaluation of LY573144 (lasmiditan) in a preclinical model of medication overuse headache","volume":"40","author":"Rau","year":"2020","journal-title":"Cephalalgia"},{"key":"10.1016\/j.clinthera.2021.01.020_bib96","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s40263-018-0522-8","article-title":"Polypharmacy among headache patients: a cross-sectional study","volume":"32","author":"Ferrari","year":"2018","journal-title":"CNS Drugs"},{"key":"10.1016\/j.clinthera.2021.01.020_bib97","doi-asserted-by":"crossref","DOI":"10.1177\/1178646919873925","article-title":"Serotonin syndrome: pathophysiology, clinical features, management, and potential future directions","volume":"12","author":"Scotton","year":"2019","journal-title":"Int J Tryptophan Res"},{"key":"10.1016\/j.clinthera.2021.01.020_bib98","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/cpdd.781","article-title":"Lasmiditan: its development and potential use","volume":"9","author":"Macone","year":"2020","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.clinthera.2021.01.020_bib99","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/cpdd.768","article-title":"Effects of lasmiditan on cardiovascular parameters and pharmacokinetics in healthy subjects receiving oral doses of propranolol","volume":"9","author":"Tsai","year":"2020","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.clinthera.2021.01.020_bib100","doi-asserted-by":"crossref","DOI":"10.1177\/1756286420967847","article-title":"The potential of lasmiditan in migraine","volume":"13","author":"Mecklenburg","year":"2020","journal-title":"Ther Adv Neurol Disord"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291821000473?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291821000473?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:54:22Z","timestamp":1758963262000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291821000473"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":98,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S0149291821000473"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2021.01.020","relation":{},"ISSN":["0149-2918"],"issn-type":[{"type":"print","value":"0149-2918"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rational Use of Lasmiditan for Acute Migraine Treatment in Adults: A Narrative Review","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2021.01.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}